We work onFibrobodies®: Pan-fibrosis drug delivery vectors

In this pivotal imaging study we will validate the targeting ability of our lead Fibrobody® against PDGFRB, in patients suffering fibrosis. At the same time, the study will help us to identify those patients that would benefit most from Fibrobody-based therapy.  

Our lead FDC program focuses on creating Fibrobody® Conjugates based on our lead Fibrobody® against PDGFRB, that carry potent anti-fibrotic drugs to activated myofibroblasts in the liver.    

This exciting program explores the use Fibrobodies® as vectors for highly effective therapeutic siRNAs. These entities are notoriously ineffective in reaching the intended cells. Fibrobody®-siRNA Conjugates may take the best of both worlds. This project is a collaboration with  (Big) Pharma.

This program focuses on creating Fibrobody® Conjugates that carry potent anti-fibrotic drugs for the treatment of Interstitial Pulmonary Fibrosis. 

This exciting program explores the use Fibrobodies® as vectors for highly effective therapeutic micro RNA inhibitors for the treatment of chronic kidney disease.

This program explores the concept of using Fibrobodies® as vectors to carry potent kinase inhibitors to fibrotic ('stenotic') lesions in the gut of patients suffering Crohn's disease.